44.05

0.31% -0.11

Exelixis Inc (EXEL)

Overview News Price History Option Chain Financials Why EXEL Down? Discussions Forecast

Exelixis Inc stock is traded at $44.05, with a volume of 637.51K. It is down -0.31% in the last 24 hours and up +2.31% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Previous Close:

$44.16

Open:

$43.82

24h Volume:

637.51K

Relative Volume:

0.22

Market Cap:

$11.60B

Revenue:

$2.17B

Net Income/Loss:

$521.27M

P/E Ratio:

24.89

EPS:

1.77

Net Cash Flow:

$633.79M

1W Performance:

+0.93%

1M Performance:

+2.31%

6M Performance:

+27.61%

1Y Performance:

+99.30%

1-Day Range:

$43.63

$44.21

1-Week Range:

$43.39

$48.74

52-Week Range:

$21.86

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name

Exelixis Inc

Sector

Healthcare (1163)

Industry

Biotechnology (657)

Phone

(650) 837-7000

Address

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Employee

1,147

Twitter

@exelixisinc

Next Earnings Date

2025-02-11

Latest SEC Filings

EXEL's Discussions on Twitter

Compare EXEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXEL Exelixis Inc	44.07	11.60B	2.17B	521.27M	633.79M	1.77
VRTX Vertex Pharmaceuticals Inc	469.07	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	556.05	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	323.74	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.81	28.51B	3.81B	-644.79M	-669.77M	-6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform
Sep-19-24	Initiated	UBS	Neutral
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-23	Initiated	BTIG Research	Buy
Dec-15-23	Initiated	Citigroup	Buy
Sep-26-23	Initiated	H.C. Wainwright	Buy
Aug-22-23	Reiterated	Oppenheimer	Outperform
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight
May-10-23	Resumed	Piper Sandler	Overweight
Mar-09-23	Initiated	Wells Fargo	Overweight
Jan-26-23	Initiated	Credit Suisse	Outperform
Oct-18-22	Initiated	JMP Securities	Mkt Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-03-21	Resumed	Jefferies	Buy
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Reiterated	H.C. Wainwright	Buy
Jun-15-21	Initiated	H.C. Wainwright	Buy
May-18-21	Resumed	Goldman	Sell
Mar-31-21	Initiated	Credit Suisse	Outperform
Mar-12-21	Initiated	Wolfe Research	Outperform
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Nov-13-19	Initiated	BofA/Merrill	Buy
Mar-18-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-17-18	Initiated	Goldman	Neutral
Sep-10-18	Initiated	Morgan Stanley	Underweight
May-11-18	Reiterated	Needham	Buy
Oct-17-17	Reiterated	Needham	Buy
Oct-17-17	Reiterated	RBC Capital Mkts	Outperform
Oct-16-17	Reiterated	SunTrust	Buy
Sep-22-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-12-17	Reiterated	Needham	Buy
Jul-14-17	Initiated	SunTrust	Buy
Mar-31-17	Initiated	Needham	Buy
Mar-16-17	Initiated	Oppenheimer	Perform
Feb-28-17	Downgrade	Stifel	Buy → Hold
Nov-03-16	Initiated	Deutsche Bank	Buy
Oct-10-16	Upgrade	Piper Jaffray	Neutral → Overweight
Sep-15-16	Reiterated	Stifel	Buy

View All

Exelixis Inc Stock (EXEL) Latest News

Jun 18, 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance

Jun 18, 2025

Jun 14, 2025

How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com

Jun 14, 2025

Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada

Jun 14, 2025

Jun 13, 2025

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance

Jun 13, 2025

Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus

Jun 12, 2025

Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada

Jun 12, 2025

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025

Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st

Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus

Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus

Jun 12, 2025

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks

Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus

Jun 12, 2025

Jun 10, 2025

Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily

Jun 10, 2025

Jun 09, 2025

Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media

Jun 09, 2025

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN

Jun 09, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance

Jun 09, 2025